Findings

What do systematic reviews say?

77 questions · 78 findings · 13 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 10.3%GRADE not reported 3 · 3.8%Very low 16 · 20.5%Low 20 · 25.6%Moderate 10 · 12.8%High 21 · 26.9%

Intervention not reported

rhIGF‐I, all doses ‐ injection site inflammation/reaction · patients with amyotrophic lateral sclerosis/motor neuron disease

1 finding from 1 review

Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor… 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 779 participants
Low

Intervention not reported

Tracheostomy‐free survival · patients with amyotrophic lateral sclerosis

1 finding from 1 review

Creatine for amyotrophic lateral sclerosis/motor neuron disease 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 386 participants
High

Intervention not reported

ALSFRS‐R slope Change in ALSFRS‐R / month · patients with amyotrophic lateral sclerosis

1 finding from 1 review

Creatine for amyotrophic lateral sclerosis/motor neuron disease 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 386 participants
High

Intervention not reported

FVC Slope Change in FVC / month · patients with amyotrophic lateral sclerosis

1 finding from 1 review

Creatine for amyotrophic lateral sclerosis/motor neuron disease 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 211 participants
High

Any CNTF vs placebo

Deaths · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Any CNTF showed no clear difference in deaths compared with placebo (high certainty).

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
RR 1.07 [0.81, 1.41]
2 studies · 1300 participants
High

Any CNTF vs placebo

Muscle strength · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1300 participants
High

Any CNTF vs placebo

FVC (% predicted) Change from baseline · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1300 participants
High

Changes in quality of life (SIP) change in Sickness Impact Profile (SIP) scores (range from 0 = best health to 100 = worst health). · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
no estimate extracted
1 study · 503 participants
High

Any CNTF vs placebo

Asthenia · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Any CNTF showed no clear difference in asthenia compared with placebo (high certainty).

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
RR 1.02 [0.81, 1.28]
1 study · 570 participants
High

Any CNTF vs placebo

Nausea · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Any CNTF showed no clear difference in nausea compared with placebo (high certainty).

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
RR 1.35 [0.92, 1.99]
1 study · 570 participants
High

Any CNTF vs placebo

Increased salivation · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Any CNTF showed no clear difference in increased salivation compared with placebo (high certainty).

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
RR 1.08 [0.78, 1.5]
1 study · 570 participants
High

Modafinil vs placebo

Fatigue · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Modafinil vs placebo

Adverse events · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Exercise vs usual care

Fatigue · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Exercise vs usual care

Adverse events · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Inspiratory muscle training vs sham

Fatigue · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Inspiratory muscle training vs sham

Adverse events · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Repetitive transcranial magnetic stimulation (rTMS) vs sham

Fatigue · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Repetitive transcranial magnetic stimulation (rTMS) vs sham

Adverse events · people with ALS/MND

1 finding from 1 review

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Non‐invasive ventilation vs usual care

Survival · people with ALS

1 finding from 1 review

Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Moderate